BEYFORTUS contains nirsevimab-alip, an IgG1κ monoclonal antibody that acts as a respiratory syncytial virus F protein-directed fusion inhibitor. It is formulated as a sterile injection for intramuscular use, available in pre-filled syringes at two strengths: 0.5 mL containing 50 mg and 1 mL containing 100 mg of nirsevimab-alip. Key inactive ingredients include arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose.
How should I use this medication?
This medication is injected into a muscle. It is given by your care team in a hospital or clinic setting. Talk to your care team about the use of this medication in children. While it may be given to children as young as newborns for selected conditions, precautions do apply.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
This does not apply. This medication is not for regular use.
Where should I keep my medication?
This medication is given in a hospital or clinic. It will not be stored at home.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome): -Pain, redness, or irritation at injection site -Skin rash
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Bleeding disorder -Having or recent heart surgery -Low platelet levels -Taking medications that prevent or treat blood clots -An unusual or allergic reaction to nirsevimab, other medications, foods, dyes, or preservatives
What may interact with this medication?
Interactions have not been studied.
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Visit your care team for regular checks on your health.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.